Monday, 16 January 2012

Firategrast effective at reducing relapse rates


Source MS Trust:
Higher doses of firategrast produced a 49% reduction in the number of active lesions visible on MRI scans.
Firategrast is an experimental oral treatment for relapsing remitting MS. Like natalizumab (Tysabri), firategrast is though to work by preventing certain immune cells from passing through the walls of blood vessels into the central nervous system.   For more click here.